Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501799 | 0.81 | RAB9A (0.39) | ALDH1A1KDM4EGLAGAAMAPT | |
| SCHEMBL26501703 | 0.80 | MAPT (0.39) | ALDH1A1KDM4EGAAMAPTALOX12 | |
| SCHEMBL26501657 | 0.80 | ALDH1A1 (0.36) | ALDH1A1KDM4EGLAGAAMAPT | |
| SCHEMBL26501719 | 0.77 | KDM4E (0.33) | ALDH1A1KDM4EGLAGAAMAPT | |
| SCHEMBL26501518 | 0.77 | CNR2 (0.38) | RAB9ASMN1; SMN2 | |
| SCHEMBL26501684 | 0.74 | SLC40A1 (0.36) | ALDH1A1GAAMAPTHPGDRAB9A | |
| SCHEMBL26501515 | 0.73 | PANK3 (0.43) | — | |
| SCHEMBL26501678 | 0.73 | PANK3 (0.42) | P2RX3P2RX2SMN1; SMN2 | |
| SCHEMBL26501676 | 0.71 | PANK3 (0.39) | HPGDP2RX3P2RX2L3MBTL1 | |
| SCHEMBL5513865 | 0.71 | RPS6KB2 (0.41) | ALDH1A1KDM4EGAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321092-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | ALDH1A1 715/4885KDM4E 1116/4885GLA 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.